USRE30439E - Treatment of genital tract diseases of domestic animals with prostaglandins - Google Patents
Treatment of genital tract diseases of domestic animals with prostaglandins Download PDFInfo
- Publication number
- USRE30439E USRE30439E US06/019,524 US1952479A USRE30439E US RE30439 E USRE30439 E US RE30439E US 1952479 A US1952479 A US 1952479A US RE30439 E USRE30439 E US RE30439E
- Authority
- US
- United States
- Prior art keywords
- pgf
- methyl
- dalusmus
- genital tract
- tract disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 36
- 241001465754 Metazoa Species 0.000 title claims abstract description 32
- 150000003180 prostaglandins Chemical class 0.000 title claims abstract description 17
- 210000005000 reproductive tract Anatomy 0.000 title claims description 24
- 229940094443 oxytocics prostaglandins Drugs 0.000 title description 10
- 210000002460 smooth muscle Anatomy 0.000 claims abstract description 11
- 230000004936 stimulating effect Effects 0.000 claims abstract description 4
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 34
- 238000003556 assay Methods 0.000 claims description 12
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 10
- DLJKPYFALUEJCK-MRVZPHNRSA-N carboprost Chemical compound CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C\CCCC(O)=O DLJKPYFALUEJCK-MRVZPHNRSA-N 0.000 claims description 8
- 241000699800 Cricetinae Species 0.000 claims description 6
- 241000699694 Gerbillinae Species 0.000 claims description 6
- 206010046793 Uterine inflammation Diseases 0.000 claims description 6
- 210000001072 colon Anatomy 0.000 claims description 6
- 208000004145 Endometritis Diseases 0.000 claims description 5
- 206010052096 Hydrometra Diseases 0.000 claims description 5
- 206010037651 Pyometra Diseases 0.000 claims description 5
- 230000003509 anti-fertility effect Effects 0.000 claims description 5
- 201000002765 pyometritis Diseases 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 3
- 241000282326 Felis catus Species 0.000 claims description 3
- 241000282898 Sus scrofa Species 0.000 claims description 3
- 230000003389 potentiating effect Effects 0.000 claims 4
- 241000282465 Canis Species 0.000 claims 2
- 241000283073 Equus caballus Species 0.000 claims 2
- 241000282324 Felis Species 0.000 claims 2
- 241000824799 Canis lupus dingo Species 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 abstract 1
- 150000004702 methyl esters Chemical class 0.000 description 70
- -1 for example Chemical compound 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- YMRWVEHSLXJOCD-SCOYTADVSA-N (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3r)-3-hydroxy-4,4-dimethyloct-1-enyl]cyclopentyl]hept-5-enoic acid Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O YMRWVEHSLXJOCD-SCOYTADVSA-N 0.000 description 2
- RXYPXQSKLGGKOL-UHFFFAOYSA-N 1,4-dimethylpiperazine Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- FOBVMYJQWZOGGJ-XYRJXBATSA-N 17-phenyl-18,19,20-trinor-prostaglandin E2 Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H](C(=O)C[C@H]1O)C\C=C/CCCC(O)=O)CC1=CC=CC=C1 FOBVMYJQWZOGGJ-XYRJXBATSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000006374 Uterine Cervicitis Diseases 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 206010008323 cervicitis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- QFUSOYKIDBRREL-NSCUHMNNSA-N (e)-but-2-en-1-amine Chemical compound C\C=C\CN QFUSOYKIDBRREL-NSCUHMNNSA-N 0.000 description 1
- IMPVDANDCDGWFM-SLESNMHTSA-N (z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e,3s)-3-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O IMPVDANDCDGWFM-SLESNMHTSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- YQOPNAOQGQSUHF-UHFFFAOYSA-N 1-propan-2-ylpyrrolidine Chemical compound CC(C)N1CCCC1 YQOPNAOQGQSUHF-UHFFFAOYSA-N 0.000 description 1
- LLVVDFDWPQHXBA-QEJIITRLSA-N 11-Deoxy-16,16-dimethyl-PGE2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1CCC(=O)[C@@H]1C\C=C/CCCC(O)=O LLVVDFDWPQHXBA-QEJIITRLSA-N 0.000 description 1
- LLQBSJQTCKVWTD-NFUXFLSFSA-N 13,14-dihydroprostaglandin F2alpha Chemical compound CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O LLQBSJQTCKVWTD-NFUXFLSFSA-N 0.000 description 1
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 description 1
- LJDSTRZHPWMDPG-UHFFFAOYSA-N 2-(butylamino)ethanol Chemical compound CCCCNCCO LJDSTRZHPWMDPG-UHFFFAOYSA-N 0.000 description 1
- NNWUEBIEOFQMSS-UHFFFAOYSA-N 2-Methylpiperidine Chemical compound CC1CCCCN1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 description 1
- RAQDKJJAUOPRQM-UHFFFAOYSA-N 2-[n-(2-hydroxyethyl)-4-(2-methylbutan-2-yl)anilino]ethanol Chemical compound CCC(C)(C)C1=CC=C(N(CCO)CCO)C=C1 RAQDKJJAUOPRQM-UHFFFAOYSA-N 0.000 description 1
- IOAOAKDONABGPZ-UHFFFAOYSA-N 2-amino-2-ethylpropane-1,3-diol Chemical compound CCC(N)(CO)CO IOAOAKDONABGPZ-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- JCBPETKZIGVZRE-UHFFFAOYSA-N 2-aminobutan-1-ol Chemical compound CCC(N)CO JCBPETKZIGVZRE-UHFFFAOYSA-N 0.000 description 1
- MWGATWIBSKHFMR-UHFFFAOYSA-N 2-anilinoethanol Chemical compound OCCNC1=CC=CC=C1 MWGATWIBSKHFMR-UHFFFAOYSA-N 0.000 description 1
- RGHPCLZJAFCTIK-UHFFFAOYSA-N 2-methylpyrrolidine Chemical compound CC1CCCN1 RGHPCLZJAFCTIK-UHFFFAOYSA-N 0.000 description 1
- XSDVSOQSNGGUFY-GWSKAPOCSA-N 20-ethyl PGF2alpha Chemical compound CCCCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XSDVSOQSNGGUFY-GWSKAPOCSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-UAAPODJFSA-N 5-trans-PGF2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C\CCCC(O)=O PXGPLTODNUVGFL-UAAPODJFSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AKNUHUCEWALCOI-UHFFFAOYSA-N N-ethyldiethanolamine Chemical compound OCCN(CC)CCO AKNUHUCEWALCOI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- YOUGRGFIHBUKRS-UHFFFAOYSA-N benzyl(trimethyl)azanium Chemical compound C[N+](C)(C)CC1=CC=CC=C1 YOUGRGFIHBUKRS-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- HNPFPERDNWXAGS-NFVOFSAMSA-N latanoprost free acid Chemical compound C([C@@H](O)CCC=1C=CC=CC=1)C[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O HNPFPERDNWXAGS-NFVOFSAMSA-N 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000003529 luteolytic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- XJINZNWPEQMMBV-UHFFFAOYSA-N n-methylhexan-1-amine Chemical compound CCCCCCNC XJINZNWPEQMMBV-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- JJPVWQWOOQYHCB-UHFFFAOYSA-N triethyl(phenyl)azanium Chemical compound CC[N+](CC)(CC)C1=CC=CC=C1 JJPVWQWOOQYHCB-UHFFFAOYSA-N 0.000 description 1
- RKBCYCFRFCNLTO-UHFFFAOYSA-N triisopropylamine Chemical compound CC(C)N(C(C)C)C(C)C RKBCYCFRFCNLTO-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
Definitions
- genital tract diseases of female domestic animals are known to produce significant morbidity and mortality.
- the cervix, vagina, uterus are prime sites for the formation and development of numerous purulent genital tract diseases, such as pyometra, mucometra, metritis, endometritis, vaginitis, and cervicitis.
- prostaglandins Both naturally occuring prostaglandins and prostaglandin analogs are known in the art.
- the naturally occuring prostaglandins have the prostanoic acid skelton, and carbon atom numbering illustrated by formula I: ##STR1## See Bergstrom, et al. Pharmacol. Rev. 20, 1 (1968) and references cited therein.
- prostaglandin E 2 (PGE 2 ) exhibits the following structure: ##STR2##
- prostaglandin analog herein refers to those compounds structurally related to the prostaglandins (in that they exhibit a cyclopentane, or adjacently homologous cycloalkane, ring and a pair of side chains attached to adjacent carbon atoms of the ring) which retain characteristic biological properties of the prostaglandins. See Bergstrom, cited above. Various structural modifications of the prostaglandins are known to produce useful prostaglandin analogs.
- the replacement of the carboxy with a hydroxymethyl or aminomethyl is known; substitution of a methyl, ethyl, or fluoro for a hydrogen at, for example, C-2 or C-16, and replacement of a methylene by an oxa or thia at, for example C-5 is known.
- partially deoxygenated prostaglandins are known to be useful prostaglandin analogs. Accordingly, 9-deoxy, 11-deoxy, and 15-deoxy-prostaglandins are known.
- prostaglanin analogs wherein the double bonds of, for example, PGF 2 ⁇ are shifted, e.g., cis-4,5-didehydro-PGF 1 ⁇ , or replaced by triple bonds, e.g., 13,14-didehydro-PGF 2 ⁇ .
- bicyclic large ringed lactones wherein the C-1 carboxyl forms a lactone with a ring or side chain hydroxyl, at C-9, C-11, or C-15.
- prostaglandin-type compound refers to any prostaglandin or prostaglandin-analog.
- prostaglandins in domestic animals, especially in regulation of the reproductive cycle, is known in the art. See, for example Lauderdale, J. W., J. Anim. Sci. 35:426 (1972); Lauderdale, J. W. et al., J. Anim. Sci. 38:964 (1974); Miller, R. A., et al., J. Anim. Sci. 41:369 (1975); and Hafez, Ed., Reproduction of Farm Animals, 3rd. Edition, Lea and Febizer, (1974), pp.
- THAM tris(hydroxymethyl)aminomethane
- the present invention comprises:
- a method for treating a female domestic animal suffering from a purulent genital tract disease which comprises:
- DALUSMUS-PG domestic animal luteolytic-uterine smooth muscle stimulating prostaglandin
- the present invention simply and effectively treats various purulent diseases of the female domestic animal genital tract, but does not require the use of surgical techniques which are often otherwise required. Accordingly, the present invention avoids the disadvantages in this prior art treatment: the threat to the life of the disease-compromised animal, the destruction of its reproductive potential and the uneconomic nature of the treatment due to the high cost of animal surgery.
- the present invention thus provides a surprising and unexpected advance in the treatment of these diseases.
- domestic animals within the scope of the present invention include sheep, cattle, horses, swine, and particularly and especially dogs and cats, the latter exhibiting an especially high incidence of the above diseases.
- the term "domestic animal” is further extended to include those mammals held in captivity by man, as for example, in zoological parks.
- DALUSMUS-PG's domestic animal luteolytic-uterine smooth muscle stimulating prostaglandins
- DALUSMUS-PG's are herein defined to be those prostaglandin-type compounds known in the art which are at least 30 to 50 percent as active as PGF 2 ⁇ in a standard laboratory assay for determining smooth muscle and luteolytic effects of prostaglandin-type compounds on mammals.
- the DALUSMUS-PG's are readily and efficiently identified by comparing the potency of any prostaglandin-type compound to PGF 2 ⁇ in a gerbil colon smooth muscle assay and a hamster antifertility assay, respectively. Methods for effecting these comparisons are readily available to those of ordinary skill in the art.
- any prostaglandin-type compound exhibiting at least 30 percent to 50 percent of the potency of PGF 2 ⁇ in both of these screens represents a DALUSMUS-PG.
- Particularly and especially preferred for the present purposes are DALUSMUS-PG's wherein the potency in either of these screens is at least 100 percent of the potency of PGF 2 ⁇ , for example, PGF 2 ⁇ , THAM salt.
- prostaglandin-type compounds which are DALUSMUS-PG's are:
- DALUSMUS-PG's various known pharmacologically acceptable salts are used in place of the free acids or methyl esters enumerated above.
- known salts are those with pharmaceutically acceptable metal cations, ammonium amine cations, quaternary ammonium cations, and basic amino acid cations.
- prostaglandin salts those derived from the alkali metals, e.g., lithium, sodium, and potassium, and from the alkaline earth metals, e.g., magnesium and calcium, and also the cationic forms of other metals, e.g., aluminum, zinc, and iron.
- amine cations those derived from primary, secondary, or tertiary amines.
- suitable amines are methylamine, dimethylamine, trimethylamine, ethylamine, dibutylamine, triisopropylamine, N-methyl hexylamine, decylamine, dodecylamine, allylamine, crotylamine, cyclopentylamine, dicyclohexylamine, benzylamine, dibenzylamine, ⁇ -phenylethylamine, ⁇ -phenylethylamine, ethylenediamine, diethylenetriamine, and like aliphatic, cycloaliphatic, and araliphatic amines containing up to and including about 18 carbon atoms, as well as heterocyclic amines, e.g., piperidine, morpholine, pyrrolidine, piperazine, and lower-alkyl derivatives thereof, e.g., 1-
- quaternary ammonium cations tetramethylammonium, tetraethylammonium, benzyltrimethylammonium, phenyltriethylammonium, and the like.
- the purulent genital tract diseases of female domestic animals are those described above, particularly in the Background of The Invention.
- the present invention requires the use of an amount of DALUSMUS-PG which is effective to cure the purulent genital tract disease.
- DALUSMUS-PG is preferably administered either one or twice daily.
- the treatment regiment is continued until the clinical manifestations of the disease begin to subside, ordinarily after 1 to 2 days of treatment. However, the treatment is repeated within 5 to 10 days after the initial administration if during this period the regression of the clinical symptoms of the disease is incomplete.
- the preferred route of administration is parenteral, especially intermuscular and subcutaneous.
- the DALUSMUS-PG is conventially formulated for parenteral administration by known methods.
- oral formulation in liquids or tablets
- vaginal formulation preferably as suppositories, although DALUSMUS-PG-impregnated silastic devices are also employed
- administration is effected by these routes.
- Effective dosage of the DALUSMUS-PG depends upon the potency of the DALUSMUS-PG relative to PGF 2 ⁇ , for which doses on the order to 1.0 mg./kg./day for subcutaneous or intramuscular administration are employed. However, for any animal the dosages are varied within a wide range when in the opinion of the attending veterinarian the animal is receiving too little PG (i.e., therapeutic progress is too slow or absent) or too much PG (i.e., side effects, notably diarrhea and vomiting, are too intense or too prolonged after administration). Thus for PGF 2 ⁇ doses in the range of 0.01-1.0 mg./kg./day are employed. Further employing oral or vaginal routes of administration require somewhat higher doses of DALUSMUS-PG than are required by parenteral administration, i.e. from two to 10 times the corresponding dose.
- the dosage is readily determined by the attending veterinarian, employing known methods. Thus, for example, the veterinarian would initiate treatment at the low end of the dosage range for PGF 2 ⁇ , and thereafter rapidly adjust the dosage upward or downward, based on animal response, as described above. In any event for DALUSMUS-PG's other than PGF 2 ⁇ the parenteral dose should not exceed 10 times the maximum dose of PGF 2 ⁇ indicated above.
- a further aspect of the present invention is the concomitant administration of antibiotic with the DALUSMUS-PG, in an amount effective to treat or prevent an infection associated with the purulent genital tract disease.
- Preferred antibiotics are a penicillin, a tetracycline, lincomycin, clindamycin, chloramphenicol, and streptomycin.
- the use of the antibiotic is either therapeutic (i.e., in the amount known to be useful in treatment of an existing infectious condition) or prophylactic (i.e., in an amount effective to prevent or forestall the development of an infection associated with the purulent genital tract disease).
- therapeutically the preferred method of treatment requires a culture to be taken which will determine antibiotic sensitivity to the infecting organism and thus aid in a rational selection of the antibiotic.
- the antibiotic can be administered by the same or a different route as the DALUSMUS-PG, but in any case as is known in the art for antibiotics administration to animals.
Abstract
The treatment of purulent diseases of the female genital track of domestic animals by administration of an amount of a domestic animal luteolytic-uterine smooth muscle stimulating prostaglandin (DALUSMUS-PG) effective to cure said disease is disclosed.
Description
A wide variety of genital tract diseases of female domestic animals are known to produce significant morbidity and mortality. The cervix, vagina, uterus are prime sites for the formation and development of numerous purulent genital tract diseases, such as pyometra, mucometra, metritis, endometritis, vaginitis, and cervicitis.
The diagnosis and treatment of each of the above named diseases is readily accomplished by a veterinarian ordinarily skilled in the treatment of domestic animals. Such a .[.diagonis.]. .Iadd.diagnosis .Iaddend.and treatment proceeds from a recognition of the known characteristics of each of these diseases and the employment of one of the known modalities of treatment. For example, ovariohysterectomy is employed in pyometra and mucometra, and chronic cases of metritis. However, this use of surgery, aside from the obvious destruction of the animal's reproductive potential, is not indicated in many cases for economic reasons, thus necessitating the sacrifice or other disposition of the animal. In other genital tract diseases, such as acute episodes of metritis, endometritis, cervicitis and vaginitis, treatment with antibiotics is often successfully, although for severe or chronic cases surgical treatment is required if the animal is to be restored to good health.
Both naturally occuring prostaglandins and prostaglandin analogs are known in the art. The naturally occuring prostaglandins have the prostanoic acid skelton, and carbon atom numbering illustrated by formula I: ##STR1## See Bergstrom, et al. Pharmacol. Rev. 20, 1 (1968) and references cited therein. For example, prostaglandin E2 (PGE2) exhibits the following structure: ##STR2##
The term prostaglandin analog herein refers to those compounds structurally related to the prostaglandins (in that they exhibit a cyclopentane, or adjacently homologous cycloalkane, ring and a pair of side chains attached to adjacent carbon atoms of the ring) which retain characteristic biological properties of the prostaglandins. See Bergstrom, cited above. Various structural modifications of the prostaglandins are known to produce useful prostaglandin analogs. For example, the replacement of the carboxy with a hydroxymethyl or aminomethyl is known; substitution of a methyl, ethyl, or fluoro for a hydrogen at, for example, C-2 or C-16, and replacement of a methylene by an oxa or thia at, for example C-5 is known. Further, partially deoxygenated prostaglandins are known to be useful prostaglandin analogs. Accordingly, 9-deoxy, 11-deoxy, and 15-deoxy-prostaglandins are known. Further, there are known prostaglanin analogs wherein the double bonds of, for example, PGF2α are shifted, e.g., cis-4,5-didehydro-PGF1α, or replaced by triple bonds, e.g., 13,14-didehydro-PGF2α. Finally there are known bicyclic large ringed lactones wherein the C-1 carboxyl forms a lactone with a ring or side chain hydroxyl, at C-9, C-11, or C-15.
As used herein, the term prostaglandin-type compound refers to any prostaglandin or prostaglandin-analog.
The use of prostaglandins in domestic animals, especially in regulation of the reproductive cycle, is known in the art. See, for example Lauderdale, J. W., J. Anim. Sci. 35:426 (1972); Lauderdale, J. W. et al., J. Anim. Sci. 38:964 (1974); Miller, R. A., et al., J. Anim. Sci. 41:369 (1975); and Hafez, Ed., Reproduction of Farm Animals, 3rd. Edition, Lea and Febizer, (1974), pp. 432-436 and references cited therein which describe method of administration and the effect of subcutaneous or intramuscular injection of the tris(hydroxymethyl)aminomethane (THAM) salt of PGF2α on the estrus cycle of domestic animals and discuss the desirability and usefulness of such activity.
The present invention comprises:
a method for treating a female domestic animal suffering from a purulent genital tract disease which comprises:
administering to said animal an amount of a domestic animal luteolytic-uterine smooth muscle stimulating prostaglandin (DALUSMUS-PG) effective to cure said disease.
The present invention simply and effectively treats various purulent diseases of the female domestic animal genital tract, but does not require the use of surgical techniques which are often otherwise required. Accordingly, the present invention avoids the disadvantages in this prior art treatment: the threat to the life of the disease-compromised animal, the destruction of its reproductive potential and the uneconomic nature of the treatment due to the high cost of animal surgery. The present invention thus provides a surprising and unexpected advance in the treatment of these diseases.
Domestic animals within the scope of the present invention include sheep, cattle, horses, swine, and particularly and especially dogs and cats, the latter exhibiting an especially high incidence of the above diseases. Further, as used herein, the term "domestic animal" is further extended to include those mammals held in captivity by man, as for example, in zoological parks.
Those prostaglandin-type compounds effective for the present purpose are the domestic animal luteolytic-uterine smooth muscle stimulating prostaglandins (DALUSMUS-PG's), which are herein defined to be those prostaglandin-type compounds known in the art which are at least 30 to 50 percent as active as PGF2α in a standard laboratory assay for determining smooth muscle and luteolytic effects of prostaglandin-type compounds on mammals. In particular, the DALUSMUS-PG's are readily and efficiently identified by comparing the potency of any prostaglandin-type compound to PGF2α in a gerbil colon smooth muscle assay and a hamster antifertility assay, respectively. Methods for effecting these comparisons are readily available to those of ordinary skill in the art. See Weeks, et al., J. Pharmacol. acol. Exp. Ther. 186:64-74 (1973) for a description of a gerbil colon smooth muscle assay and J. Pharm. and Exp. Ther. 186:67 (1973), for a description of a hamster antifertility assay. Accordingly, any prostaglandin-type compound exhibiting at least 30 percent to 50 percent of the potency of PGF2α in both of these screens represents a DALUSMUS-PG. Particularly and especially preferred for the present purposes are DALUSMUS-PG's wherein the potency in either of these screens is at least 100 percent of the potency of PGF2α, for example, PGF2α, THAM salt.
Examples of prostaglandin-type compounds which are DALUSMUS-PG's are:
8β,12α-PGE1, methyl ester;
17-phenyl-18,19,20-trinor-8β,12α-PGE1, methyl ester;
17-phenyl-18,19,20-trinor-13,14-dihydro-8β,12α-PGE1, methyl ester;
15-methyl-8β,12α-PGE1, methyl ester;
15-Methyl-cis-4,5-didehydro-PGE1, methyl ester;
16,16-Dimethyl-cis-4,5-didehydro-PGE1, methyl ester;
17-Phenyl-18,19,20-trinor-cis-4,5-didehydro-PGE1, methyl ester;
5-Oxa-16-(p-fluorophenoxy)-17,18,19,20-tetranor-PGE1, methyl ester;
15-Methyl-PGE1 ;
16-Phenoxy-17,18,19,20-tetranor-PGE1 ;
cis-4,5-Didehydro-16,16-dimethyl-PGE1 ;
2,2-Difluoro-15-methyl-PGE1, methyl ester;
16,16-Difluoro-5-oxa-PGE1, methyl ester;
16,16-Difluoro-13,14-dihydro-PGE1, methyl ester;
15-Methyl-PGE2 ;
16-Methyl-PGE2 ;
15-Methyl-PGE2, methyl ester;
16,16-Dimethyl-PGE2 ;
17-Phenyl-18,19,20-trinor-PGE2 ;
8β,12α-PGE2, methyl ester
17-Cyclohexyl-18,19,20-trinor-PGE2 ;
15-Methyl-8β,12α-PGE2, methyl ester;
15-Methyl-PGE2, isopropyl ester;
15-Methyl-PGE2, p-acetamidophenyl ester;
17-Phenyl-18,19,20-trinor-8β,12α-PGE2, methyl ester;
11-Deoxy-16,16-dimethyl-PGE2 ;
16,16-Difluoro-PGE2, methyl ester;
15-epi-cis-13-16,16-Difluoro-PGE2, methyl ester;
16-Phenoxy -17,18,19,20-tetranor-PGE2 ;
15-epi-16-phenoxy-17,18,19,20-tetranor-8β,12α-PGE2, methyl ester;
16-Phenoxy-17,18,19,20-tetranor-8β,12α-PGE2, methyl ester;
17-Phenyl-18,19,20-trinor-8β,12α-PGE2 ;
8β,12α-PGE2 ;
15-epi-cis-13-PGE2, methyl ester;
13,14-Didehydro-PGE2, methyl ester;
17-Phenyl-18,19,20-trinor-PGE2, p-acetylphenyl ester;
15-methyl-17-phenyl-18,19,20-trinor-PGE2, methyl ester;
17,18,19,20-Tetranor-16-phenoxy-PGE2, p-acetylphenyl ester;
11-Deoxy-16-phenoxy-17,18,19,20-tetranor-PGE2 ;
15-Methyl-16-phenoxy-17,18,19,20-tetranor-PGE2, methyl ester;
15-epi-15-Methyl-16-phenoxy-17,18,19,20-tetranor-PGE2, methyl ester;
2a,2b-Dihomo-17,18,19,20-tetranor-16-phenoxy-PGE2 ;
11-Deoxy-16,16-difluoro-PGE2, methyl ester;
2a,2b-Dihomo-15-methyl-17-phenyl-18,19,20-trinor-PGE2, methyl ester;
13,14-Didehydro-PGE2 ;
16-(m-chlorophenoxy)-17,18,19,20-tetranor-PGE2 ;
2,2-Difluoro-16-(m-trifluoromethyl phenoxy)-17,18,19,20-tetranor-PGE2, 15-methyl ether, methyl ester;
2,2,16,16-Tetrafluoro-PGE2, methyl ester;
15-epi-cis-13.[.,.]..Iadd.-.Iaddend.2,2-Difluoro-PGE2, methyl ester;
16,16-Difluoro-13,14-dihydro-PGE2, methyl ester;
racemic-17-Phenyl-18,19,20-trinor-PGF1α ;
15-Methyl-PGF1α ;
racemic-15-methyl-17-phenyl-18,19,20-trinor-PGF1α ;
15-Methyl-PGF1α, methyl ester;
cis-4,5-Didehydro-PGF1α ;
5-oxa-PGF1α;
17-Phenyl-18,19,20-trinor-PGF1α ;
13,14-Dihydro-17-phenyl-18,19,20-trinor-PGF1α ;
15-Methyl-cis-4,5-didehydro-PGF1α, methyl ester;
cis-4,5-Didehydro-PGF1α, methyl ester;
16,16-Dimethyl-cis-4,5-didehydro-PGF1α, methyl ester;
5-oxa-16-(p-fluorophenoxy)-17,18,19,20-tetranor-PGF1α, methyl ester;
cis-4,5-Didehydro-16,16-dimethyl-PGF1α ;
15-Methyl-cis-4,5-didehydro-PGF1α ;
PGF2α ;
PGF2α, 1-lysine salt;
PGF2α, 1-arginine salt;
5,6-trans-PGF2α ;
15-Methyl-PGF2α ;
17-Phenyl-18,19,20-trinor-PGF2α, methyl ester;
17-Phenyl-18,19,20-trinor-PGF2α ;
20-Ethyl-PGF2α ;
15-Methyl-PGF2α, methyl ester;
17-Phenyl-18,19,20-trinor-PGF2α, 15-methyl ether;
20-Methyl-PGF2α ;
16,16-Dimethyl-PGF2α ;
16-Methyl-PGF2α ;
16-Methyl-16-phenoxy-18,19,20-trinor-PGF2α ;
15-Methyl-15-epi-PGF2α, methyl ester;
16,16-Dimethyl-17-phenyl-18,19,20-trinor-PGF2α ;
PGF2α, 15-methyl ether;
16-Phenoxy-17,18,19,20-tetranor-PGF2α ;
PGF2α, isopropyl ester;
15-methyl-17-phenyl-18,19,20-trinor-PGF2α, methyl ester;
16-Fluoro-PGF2α ;
13,14-Dihydro-PGF2α ;
17-p-chlorophenyl-18,19,20-trinor-PGF2α, ethyl ester;
16,16-Dimethyl-PGF2α, methyl ester;
16-Methyl-16-phenoxy-18,19,20-trinor-PGF2α, methyl ester;
17-Cyclohexyl-18,19,20-trinor-PGF2α ;
20-Ethyl-15-methyl-PGF2α, methyl ester,
17-(p-fluorophenyl)-18,19,20-trinor-PGF2α ;
15-epi-2,2-difluoro-15-methyl-PGF2α, methyl ester;
2,2-Difluoro-15-methyl-PGF2α, methyl ester;
15-Methyl-11β-PGF2α, methyl ester;
2,2-Difluoro-17-phenyl-18,19,20-trinor-PGF2α, methyl ester;
15-Methyl-13,14-dihydro-PGF2α, methyl ester;
15 -Methyl-PGF2α, methyl ester, 15-methyl ether;
13,14-Didehydro-15-epi-PGF2α, methyl ester;
15-epi-cis-13-16,16-Difluoro-PGF2α, methyl ester;
15-epi-16,16-Difluoro-PGF2α, methyl ester;
2-Decarboxy-2-hydroxymethyl-16,16-dimethyl-PGF2α ;
PGF2α, p-acetamidophenyl ester;
PGF2α, biphenyl ester;
PGF2α, p-benzaldehyde semicarbazone ester;
15-epi-15-Ethyl-PGF2α, methyl ester;
16,16,15-Trimethyl-PGF2α, methyl ester;
13,14-Didehydro-PGF2α, methyl ester;
(12E)-12,13-Didehydro-13,14-dihydro-15-methyl-PGF2α, methyl ester;
15-epi-cis-13-PGF2α, methyl ester;
13,14-Dihydro-17-phenyl-18,19,20-trinor-PGF2α ;
15-epi-cis-13-16-(p-fluorophenoxy)-17,18,19,20-tetranor-PGF2α, methyl ester;
15-epi-cis-13-PGF2α ;
16-(m-trifluoromethylphenoxy)-17,18,19,20-tetranor-PGF2α ;
15-Methyl-PGF2α, naphthyl ester;
15-Methyl-PGF2α, p-acetyl phenyl ester;
2-Decarboxy-2-aminomethyl-PGF2α ;
11β-16,16-Dimethyl-PGF2α, methyl ester;
15-Methyl-16-phenoxy-17,18,19,20-tetranor-PGF2α,methyl ester;
15-epi-15-Methyl-16-phenoxy-17,18,19,20-tetranor-PGF2α, methyl ester;
13,14-Dihydro-2,2-difluoro-PGF2α, methyl ester;
2a,2b-Dihomo-17,18,19,20-tetranor-16-phenoxy-PGF2α ;
2-Decarboxy-2-aminomethyl-16,16-dimethyl-PGF2α ;
2-Decarboxy-2-aminomethyl-15-methyl-PGF2α ;
2a,2b-Dihomo-15-methyl-17-phenyl-18,19,20-trinor-PGF2α, methyl ester;
13,14-Didehydro-PGF2α ;
11-Deoxy-16,16-difluoro-PGF2α, methyl ester;
2,2,16,16-Tetrafluoro-PGF2α, methyl ester;
16-(m-chlorophenoxy)-17,18,19,20-tetranor-PGF2α ;
15-epi-cis-13-2,2-Difluoro-PGF2α, methyl ester;
2,2-Difluoro-16-(m-trifluoromethylphenoxy)-17,18,19,20-tetranor-PGF2.alpha., 15-methyl ether, methyl ester;
PGF2α, 2-methyl phenyl ester;
PGF2α, 2,6-dimethyl phenyl ester;
PGF2α, Phenyl ester;
16,16-Difluoro-13,14-dihydro-PGF2α, methyl ester;
13,14-Dihydro-15-epi-15-methyl-PGF2α ;
17-Phenyl-18,19,20-trinor-8β,12α-PGF2α, methyl ester; and
16-Phenoxy-17,18,19,20-tetranor-8β,12α-PGF2α, methyl ester.
The above DALUSMUS-PG's are all named essentially according to the system of nomenclature described by Nelson, J. Med. Chem. 17:911 (1974).
With regard to the above list of DALUSMUS-PG's, various known pharmacologically acceptable salts are used in place of the free acids or methyl esters enumerated above. Examples of such known salts are those with pharmaceutically acceptable metal cations, ammonium amine cations, quaternary ammonium cations, and basic amino acid cations.
Known among the pharmaceutically acceptable metal cations of prostaglandin salts are those derived from the alkali metals, e.g., lithium, sodium, and potassium, and from the alkaline earth metals, e.g., magnesium and calcium, and also the cationic forms of other metals, e.g., aluminum, zinc, and iron.
Known among the pharmaceutically acceptable amine cations are those derived from primary, secondary, or tertiary amines. Examples of suitable amines are methylamine, dimethylamine, trimethylamine, ethylamine, dibutylamine, triisopropylamine, N-methyl hexylamine, decylamine, dodecylamine, allylamine, crotylamine, cyclopentylamine, dicyclohexylamine, benzylamine, dibenzylamine, α-phenylethylamine, β-phenylethylamine, ethylenediamine, diethylenetriamine, and like aliphatic, cycloaliphatic, and araliphatic amines containing up to and including about 18 carbon atoms, as well as heterocyclic amines, e.g., piperidine, morpholine, pyrrolidine, piperazine, and lower-alkyl derivatives thereof, e.g., 1-methylpiperidine, 4-ethylmorpholine, 1-isopropylpyrrolidine, 2-methylpyrrolidine, 1,4-dimethylpiperazine, 2-methylpiperidine, amantadine and the like, as well as amines containing water-solubilizing or hydrophilic groups, e.g., mono-, di-, and triethanolamine, ethyldiethanolamine, N-butylethanolamine, 2-amino-1-butanol, 2-amino-2-ethyl-1,3-propanediol, 2-amino-2-methyl-1-propanol, tris(hydroxymethyl)aminomethane, N-phenylethanolamine, N-(p-tert-amylphenyl)-diethanolamine, galactamine, N-methylglucamine, N-methylglucosamine, ephedrine, phenylephrine, epinephrine, procaine, and the like.
Known among the pharmaceutically acceptable quaternary ammonium cations are tetramethylammonium, tetraethylammonium, benzyltrimethylammonium, phenyltriethylammonium, and the like.
Known among the basic amino acid cations are arginine and lysine.
The purulent genital tract diseases of female domestic animals are those described above, particularly in the Background of The Invention.
Finally, the present invention requires the use of an amount of DALUSMUS-PG which is effective to cure the purulent genital tract disease. For this purpose a wide variety of dosage schedules and routes of administration are employed. For convenience, however, the DALUSMUS-PG is preferably administered either one or twice daily. The treatment regiment is continued until the clinical manifestations of the disease begin to subside, ordinarily after 1 to 2 days of treatment. However, the treatment is repeated within 5 to 10 days after the initial administration if during this period the regression of the clinical symptoms of the disease is incomplete.
In situations where the animal is under veterinary care the preferred route of administration is parenteral, especially intermuscular and subcutaneous. In this case, the DALUSMUS-PG is conventially formulated for parenteral administration by known methods.
However, other routes of administration can be employed when the parenteral route is not convenient. Thus oral formulation (in liquids or tablets) or vaginal formulation (preferably as suppositories, although DALUSMUS-PG-impregnated silastic devices are also employed) are undertaken and administration is effected by these routes.
Effective dosage of the DALUSMUS-PG depends upon the potency of the DALUSMUS-PG relative to PGF2α, for which doses on the order to 1.0 mg./kg./day for subcutaneous or intramuscular administration are employed. However, for any animal the dosages are varied within a wide range when in the opinion of the attending veterinarian the animal is receiving too little PG (i.e., therapeutic progress is too slow or absent) or too much PG (i.e., side effects, notably diarrhea and vomiting, are too intense or too prolonged after administration). Thus for PGF2α doses in the range of 0.01-1.0 mg./kg./day are employed. Further employing oral or vaginal routes of administration require somewhat higher doses of DALUSMUS-PG than are required by parenteral administration, i.e. from two to 10 times the corresponding dose.
For DALUSMUS-PG's other than PGF2α, the dosage is readily determined by the attending veterinarian, employing known methods. Thus, for example, the veterinarian would initiate treatment at the low end of the dosage range for PGF2α, and thereafter rapidly adjust the dosage upward or downward, based on animal response, as described above. In any event for DALUSMUS-PG's other than PGF2α the parenteral dose should not exceed 10 times the maximum dose of PGF2α indicated above.
A further aspect of the present invention is the concomitant administration of antibiotic with the DALUSMUS-PG, in an amount effective to treat or prevent an infection associated with the purulent genital tract disease. Preferred antibiotics are a penicillin, a tetracycline, lincomycin, clindamycin, chloramphenicol, and streptomycin.
The use of the antibiotic is either therapeutic (i.e., in the amount known to be useful in treatment of an existing infectious condition) or prophylactic (i.e., in an amount effective to prevent or forestall the development of an infection associated with the purulent genital tract disease). When employed therapeutically, the preferred method of treatment requires a culture to be taken which will determine antibiotic sensitivity to the infecting organism and thus aid in a rational selection of the antibiotic.
As employed concomitantly, the antibiotic can be administered by the same or a different route as the DALUSMUS-PG, but in any case as is known in the art for antibiotics administration to animals.
Claims (1)
- disease..]. .[.3. A method according to claim 2 wherein said purulent genital tract disease is endometritis..]. .[.4. A method according to claim 2 wherein said purulent genital tract disease is metritis..]. .[.5. A method according to claim 2 wherein said purulent genital tract disease is mucometra..]. .[.6. A method according to claim 2 wherein said genital tract disease is pyometra..]. .[.7. A method according to claim 6 wherein said female domestic animal is bovine, equine, or swine..]. .[.8. A method according to claim 6 wherein said domestic animal is canine or feline..]. .[.9. A method according to claim 8 wherein said DALUSMUS-PG is 15-methyl-PGF2α, THAM salt..]. .[.10. A method according to claim 8, wherein said DALUSMUS-PG is PGF2α, THAM salt or PGF2α, 1-arginine salt..]. .[.11. A method according to claim 1 wherein said DALUSMUS-PG is at least as potent as PGF2α in a gerbil colon smooth muscle assay or a hamster anifertility assay..]. .[.12. A method according to claim 1 wherein said DALUSMUS-PG is at least as potent as PGF2α in both a gerbil colon smooth muscle assay and a hamster antifertility assay..]. .[.13. A method according to claim 12 wherein said purulent genital tract disease is endometritis..]. .[.14. A method according to claim 12 wherein said purulent genital tract disease is metritis..]. .[.15. A method according to claim 12 wherein said purulent genital tract disease is mucometra..]. .[.16. A method according to claim 12 wherein said genital tract disease is pyometra..]. .[.17. A method according to claim 16 wherein said female domestic animal is bovine, equine, or swine..]. .[.18. A method according to claim 16 wherein said domestic animal is canine or feline..]. .[.19. A method according to claim 18 wherein said DALUSMUS-PG is 15-methyl-PGF2α, THAM salt..]. .[.20. A method according to claim 18 wherein said DALUSMUS-PG is PGF2α, THAM salt or PGF2α, 1-arginine salt..]. .Iadd. 21. A method for treating a female domestic dog or cat suffering from a purulent genital tract disease which comprises:administering to said dog or cat an amount of a domestic animal luteolytic-uterine smooth muscle stimulating prostaglandin (DALUSMUS-PG) effective to cure said disease. .Iaddend..Iadd. 22. A method according to claim 21, wherein said DALUSMUS-PG is at least as potent as PGF2α in a gerbil colon smooth muscle assay or a hamster antifertility assay. .Iaddend. .Iadd. 23. A method according to claim 21, wherein said DALUSMUS-PG is at least as potent as PGF2α in both a gerbil colon smooth muscle assay and a hamster antifertility assay. .Iaddend..Iadd. 24. A method according to claim 23, wherein said purulent genital tract disease is endometritis. .Iaddend..Iadd. 25. A method according to claim 23, wherein said purulent genital tract disease is metritis. .Iaddend..Iadd. 26. A method according to claim 23, wherein said purulent genital tract disease is mucometra. .Iaddend..Iadd. 27. A method according to claim 23, wherein said genital tract disease is pyometra. .Iaddend..Iadd. 28. A method according to claim 27, wherein said DALUSMUS-PG is 15-methyl-PGF2α, THAM salt. .Iaddend..Iadd. 29. A method according to claim 27, wherein said DALUSMUS-PG is PGF2α, THAM salt or PGF2α, 1-arginine salt..Iaddend.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/019,524 USRE30439E (en) | 1979-03-12 | 1979-03-12 | Treatment of genital tract diseases of domestic animals with prostaglandins |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/019,524 USRE30439E (en) | 1979-03-12 | 1979-03-12 | Treatment of genital tract diseases of domestic animals with prostaglandins |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US05/692,440 Reissue US4051238A (en) | 1976-06-03 | 1976-06-03 | Treatment of genital tract diseases of domestic animals with prostaglandins |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE30439E true USRE30439E (en) | 1980-11-25 |
Family
ID=21793667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/019,524 Expired - Lifetime USRE30439E (en) | 1979-03-12 | 1979-03-12 | Treatment of genital tract diseases of domestic animals with prostaglandins |
Country Status (1)
Country | Link |
---|---|
US (1) | USRE30439E (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US20070191320A1 (en) * | 1998-12-10 | 2007-08-16 | Nexmed Holdings, Inc. | Methods of treatment for female sexual arousal disorder |
-
1979
- 1979-03-12 US US06/019,524 patent/USRE30439E/en not_active Expired - Lifetime
Non-Patent Citations (3)
Title |
---|
Barkstrom et al., Vet. Bull. 44:808 (1974). * |
Barkstrom, Proc. XII Nordie Vet. Congress, 1974, p. 277. * |
Hinman--Annual Review of Biochemistry, vol. 41, (1972), p. 168. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US20070191320A1 (en) * | 1998-12-10 | 2007-08-16 | Nexmed Holdings, Inc. | Methods of treatment for female sexual arousal disorder |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4311707A (en) | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions | |
US4051238A (en) | Treatment of genital tract diseases of domestic animals with prostaglandins | |
EP0299914B2 (en) | 9-Halogen (Z) prostaglandin derivatives, process for their production and their use as medicines | |
EP1021402B1 (en) | Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists | |
KR20010023838A (en) | Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists | |
GB1363506A (en) | Process for the preparation of alpha-amino-penicillins and such penicillins and intermediates and pharmaceutical preparations | |
US3927213A (en) | Prostaglandin E{HD 2 {B and derivatives for reducing the side effects of anti-inflammatory agents | |
USRE30439E (en) | Treatment of genital tract diseases of domestic animals with prostaglandins | |
US3928588A (en) | Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors | |
US4707495A (en) | Peptic ulcer treatment method | |
AU609428B2 (en) | Use of carboxylic acid amides | |
HU181424B (en) | Process for preparing omega-nor-aromatic-13,14-dehydro-prostaglandins | |
CH642063A5 (en) | METHOD FOR PRODUCING PROSTAGLANDIN ANALOGS IN WHICH THE CARBONYL GROUP ON THE C-9 IS REPLACED BY A METHYLENE GROUP. | |
US4374856A (en) | Liver cytoprotection using PGE's | |
US3852465A (en) | Abortion by myometrial administration of prostaglandins | |
US3892795A (en) | 16-Methyl and 16,16 dimethyl PGA{HD 2 {B compounds | |
US4289785A (en) | Method and compositions involving prostaglandins | |
CH640847A5 (en) | Process for preparing analogues of 5,6-dihydroprostacyclin | |
US4062964A (en) | Antifertility-combinations | |
CH623569A5 (en) | ||
US4092425A (en) | Restoration of interferon response | |
DE3414509C2 (en) | ||
US3778506A (en) | Use of prostaglandins to induce medical abortion | |
US4208427A (en) | Preventing enteropooling induced diarrhea by prostacyclin or 11-oxo-prostaglandin administration | |
CH632743A5 (en) | METHOD FOR PRODUCING NEW PROSTAGLANDIN ANALOGS WITH A 4.5 DOUBLE BINDING. |